

67/2/1

Patent Application
Attorney Docket No. PC10202A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Manuel Campos, et al.:

APPLICATION NO.: 09/506,078 : Examiner: Foley, S.
FILING DATE: February 16, 2000 : Group Art Unit: 1648
TITLE: FUSION PROTEINS COMPRISING
CARRIERS THAT CAN INDUCE A DUAL
IMMUNE RESPONSE

Commissioner for Patents
Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

As discussed with Examiner Foley in a telephone Interview on June 29, 2001, this Information Disclosure Statement is being filed by hand delivery to the Examiner so that she may consider it, including the references herewith, along with the Amendment in response to the December 27, 2000 Office Action that applicants filed on June 27, 2001.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the following references cited by the applicant(s), copies of which are enclosed:

SH

1. United States Patent, 5,403,586, Russell-Jones, et al, April 4, 1995;
2. United States Patent, 5,585,264, Babiuk, et al., December 17, 1996;
3. United States Patent, 4,722,840, Valenzuela, et al., February 2, 1988;
4. United States Patent, 5,422,110, Potter, et al., June 6, 1995;
5. United States Patent, 6,086,902, Zamb, et al., July 11, 2000;
6. United States Patent, 4,975,420, Silversides, et al., December 4, 1990;
7. WO 99/02180, CSL Limited, January 21, 1999;
8. WO 86/06635, BIOTECHNOLOGY AUSTRALIA PTY. LTD., November 20, 1986;
9. WO 84/04756, CELL TECH LIMITED, December 6, 1984;
10. WO 90/02187, APPLIED RESEARCH SYSTEMS, March 8, 1990;
11. WO 92/03558, Potter, A., et al., March 5, 1992;
12. WO 96/24775, Friedman, M., August 15, 1996;
13. EP 0175261, CHIRON CORPORATION, March 26, 1986;
14. EP 0131363, CELL TECH LIMITED, January 16, 1985;
15. GB 2140810A, CELL TECH LIMITED, December 5, 1984
16. A. Ladd, Progress in the Development of Anti-LHRH Vaccine, AJRI, (1993)

SA 7/6/01
#7
01 JUL - 2 FILED: 6/2
RECEIVED
U.S. PATENT AND TRADEMARK OFFICE
JUL 1 2001

29, pp. 189-194.

SAF 17. Tikoo, S. K., et al, Molecular Cloning, Sequencing, and Expression of Functional Bovine Herpesvirus 1 Glycoprotein gIV in Transfected Bovine Cells, Journal of Virology, Oct. (1990) pp. 5132-5142.

Sharon H. Foley
9/3/01 The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

Please charge the \$180.00 fee for filing an Information Disclosure Statement after issuance of first Office Action to Deposit Account No. 16-1445. No other fee is believed necessary for filing this Information Disclosure Statement. However, if any other fee is deemed necessary for filing this Information Disclosure Statement, please also charge such fee to Deposit Account No. 16-1445.

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: June 29, 2001

Kristina L. Konstas
Kristina L. Konstas
Attorney for Applicant(s)
Reg. No. 37,864

Pfizer Inc
Patent Department, 20th Floor
235 East 42nd Street
New York, NY 10017-5755
(212) 733-6380